C07K 16/38
Against protease inhibitors of peptide structure
Official title: against protease inhibitors of peptide structure
C07K16/38 (Against protease inhibitors of peptide structure) appears on 247 US grants and 300 published applications in this corpus.
Search patents in C07K- Granted patents
- 247
- Published applications
- 300
- Assignees
- 188
- Inventors
- 643
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 3 | 0 |
| 1991 | 3 | 0 |
| 1992 | 4 | 0 |
| 1993 | 7 | 0 |
| 1994 | 7 | 0 |
| 1995 | 8 | 0 |
| 1996 | 3 | 0 |
| 1997 | 8 | 0 |
| 1998 | 13 | 0 |
| 1999 | 7 | 0 |
| 2000 | 2 | 0 |
| 2001 | 7 | 1 |
| 2002 | 4 | 7 |
| 2003 | 3 | 11 |
| 2004 | 3 | 8 |
| 2005 | 8 | 7 |
| 2006 | 5 | 8 |
| 2007 | 6 | 6 |
| 2008 | 2 | 3 |
| 2009 | 4 | 9 |
| 2010 | 1 | 6 |
| 2011 | 4 | 7 |
| 2012 | 2 | 8 |
| 2013 | 5 | 17 |
| 2014 | 6 | 17 |
| 2015 | 7 | 11 |
| 2016 | 5 | 18 |
| 2017 | 12 | 25 |
| 2018 | 17 | 19 |
| 2019 | 10 | 17 |
| 2020 | 15 | 14 |
| 2021 | 6 | 18 |
| 2022 | 11 | 23 |
| 2023 | 7 | 19 |
| 2024 | 12 | 9 |
| 2025 | 13 | 6 |
| 2026 | 4 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-A2AP antibodies and uses thereof25 Aug 2026US 12,715,932 B2Bayer Aktiengesellschaft
- Stable aqueous anti-TFPI antibody formulation18 Aug 2026US 12,708,668 B2Pfizer Inc.
- Antibodies to plasminogen activator inhibitor-1 (PAI-1) and uses thereof2 Jun 2026US 12,643,957 B2Sanofi
- Monoclonal antibody which targets TFPI24 Mar 2026US 12,583,940 B2Suzhou Alphamab Co., Ltd.
- Compositions and methods for linear and conformational site-specific antibodies and methods of making the same30 Dec 2025US 12,509,508 B2Abbratech, Inc.
- Novel methods of generating antibodies24 Sep 2026US 2026/0285952 A1Rutgers, The State University of New Jersey
- Dissolvable films and methods of their use30 Jul 2026US 2026/0216340 A1Board of Regents, The University of Texas System
- Method for promoting pathological tdp-43 protein degradation, and drug18 Jun 2026US 2026/0166131 A1Talengen International Limited
- Small cell lung cancer tumor antigens and uses thereof14 May 2026US 2026/0133192 A1Fred Hutchinson Cancer Center
- Compositions and methods for treating serpin b13 disorders30 Apr 2026US 2026/0116996 A1Regents of the University of Minnesota
Most cited
By later US patents
- Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)104US 4,603,106 AThe Rockefeller University · 1986
- Pancreatic cancer targets and uses thereof104US 7,473,531 B1Colora Corporation · 2009
- Methods of treatment using Alzheimer's amyloid polypeptide derivatives93US 5,187,153 AScios Nova Inc. · 1993
- Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay)72US 4,822,776 AThe Rockefeller University · 1989
- DNA clone of human tissue factor inhibitor58US 4,966,852 AMonsanto Company · 1990